Alzheimer's Disease Clinical Trial
— GHABSOfficial title:
Greater-Bay-Area Healthy Aging Brain Study (GHABS): Biomarker- and Neuroimaging-based Study of the Pathophysiology Characterization and Evolutionary Patterns of Alzheimer's Disease
NCT number | NCT06183658 |
Other study ID # | YL2023-001 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2021 |
Est. completion date | April 30, 2026 |
The goal of this observational study is to learn about the pathophysiology characterization and evolutionary patterns of Alzheimer's disease (AD) in South China older adults. The primary purposes are as follows: 1. The prevalence and characteristics of AD in South China's aging population 2. Identify novel biomarkers and neuroimaging techniques for early detection and intervention of AD 3. Supporting and fertilizing novel approaches and techniques for early diagnosis and intervention of AD Participants will undergo cognitive assessments, blood sample collection, and genetic testing. Some will undergo CSF collection, stool sample collection, MRI scanning, Aβ PET scanning, and tau PET scanning.
Status | Recruiting |
Enrollment | 1400 |
Est. completion date | April 30, 2026 |
Est. primary completion date | April 30, 2026 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 55 Years to 90 Years |
Eligibility | Inclusion Criteria: - This project intends to recruit men and women between the ages of 55 and 90. The inclusion criteria are as listed: - Age 55-90 years old (including 55 and 90 years old). However, people with autosomal dominant and other familial Alzheimer disease (FAD) are not limited by age. - The score of the Geriatric Depression Scale (GDS) is less than 6 points. - There is a caregiver who can maintain at least 10 hours of contact per week and can accompany volunteers to the test site for testing. - Visual and auditory acuity is sufficient for neuropsychological testing. (Including normal corrected vision and hearing) - Be in good health and are expected to be free of disease interference during the study. - Volunteers are not pregnant, lactating or have reproductive potential (that is, women must be two years after menopause or undergo sterilization surgery). - Willingness and ability to participate in longitudinal imaging studies. - A modified version of the Hachinski Ischemic scores less than or equal to 4. - Have completed grade 6 education or have good work experience (sufficient to rule out mental retardation). - Must be able to speak Mandarin fluently. - Willing to undergo multiple 3T MRI scans and at least two PET scans. - Agree to collect blood for genomic analysis (including GWAS sequencing and other analyses), AD risk and protective genes such as apolipoprotein E (APOE), klotho, etc., and biological sample storage. - Agree to collect blood for biomarker detection. - Agree to share genomic data and biomarker samples. Exclusion Criteria: - MRI brain scan screening reveals infection, infarction or other focal lesions or multiple lacunes or lacunes in key memory structures. - Any volunteers who do not meet the MRI scan requirements, including having a cardiac pacemaker, eyes, skin or metal fragments or foreign bodies in the body. - Severe depression, bipolar affective disorder described in DSM-IV in the past year. - Psychotic features, agitation or behavioral problems that may lead to difficulty complying with the protocol content in the past 3 months. - Currently using medication to treat obsessive-compulsive disorder or attention deficit disorder. - History of schizophrenia (meeting DSM-IV criteria). - History of alcohol or drug abuse or dependence within the past 2 years (metting DSM-IV criteria). - Any major systemic disease or unstable physical condition that may make longitudinal research difficult. - Clinically significant abnormalities of B12 or TFTs may interfere with the study, low B12 will be excluded. - Currently using certain psychoactive medications (e.g., certain antidepressants, neuro-depressants, chronic anxiolytics, or sedative-hypnotics). Currently using warfarin or other anticoagulants such as dabigatran, rivaroxaban, and apixaban (except lumbar puncture). - Use of prohibited drugs. - Simultaneously participating in other clinical studies involving neuropsychiatry. |
Country | Name | City | State |
---|---|---|---|
China | Shenzhen Bay Laboratory | Shenzhen | Other |
Lead Sponsor | Collaborator |
---|---|
Shenzhen Bay Laboratory | Guangdong Basic and Applied Basic Science Foundation, National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Commission |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Correlation of microbiome to Alzheimer's Disease | Correlation of microbiome to Alzheimer's Disease via relative abundance found in gut microbiome study. These data will then be correlated to Alzheimer's disease state | 1 time sampling | |
Primary | Longitudinal changes of cognitive function _ ADAS-Cog | Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) | An average of 1 year | |
Primary | Longitudinal changes of cognitive function _ MMSE, the Chinese version | Mini-mental State Examination (MMSE, the Chinese version) | An average of 1 year | |
Primary | Longitudinal changes of cognitive function _ MoCA-Basic | Montreal Cognitive Assessment Basic (MoCA-Basic) | An average of 1 year | |
Primary | Longitudinal functional and behavioral function _ CDR | Clinical Dementia Rating (CDR) | An average of 1 year | |
Primary | Longitudinal functional and behavioral function _ NPI | Neuropsychiatric Inventory (NPI) | An average of 1 year | |
Primary | Longitudinal functional and behavioral function _ GDS | Geriatric Depression Scale (GDS) | An average of 1 year | |
Primary | Longitudinal functional and behavioral function _ FAQ | Function Activities Questionnaire (FAQ) | An average of 1 year | |
Primary | Longitudinal functional and behavioral function _ ADL | Activity of Daily Living Scale (ADL) | An average of 1 year | |
Primary | Longitudinal functional and behavioral function _ PSQI | Pittsburgh sleep quality index (PSQI) | An average of 1 year | |
Primary | Longitudinal functional and behavioral function _ RBDSQ | REM sleep behavior disorder screening questionnaire (RBDSQ) | An average of 1 year | |
Secondary | Longitudinal changes of plasma biomarkers | Longitudinal changes of disease status as categorized by plasma biomarkers of Alzheimer's diseases over time. | An average of 1 year | |
Secondary | Longitudinal changes of CSF biomarkers | Longitudinal changes of disease status as categorized by CSF biomarkers of Alzheimer's diseases over time. | An average of 2 years | |
Secondary | Longitudinal changes in neuroimaging _ MRI images | Longitudinal change in brain structure using magnetic resonance imaging (MRI) | An average of 2 years | |
Secondary | Longitudinal changes in neuroimaging _ amyloid PET images | Longitudinal changes in amyloid deposition | An average of 2 years | |
Secondary | Longitudinal changes in neuroimaging _ tau PET images | Longitudinal changes in tau deposition | An average of 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02089555 -
African American Alzheimer's Progression Markers - CSF and Neuro-Imaging
|
N/A |